Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- AcarixPeer-Reviewed Study Confirms CADScor System Can Diagnose Heart Failure With Far Fewer False Positives Than Standard Blood TestAalborg University-led research, published in PLOS Digital Health, found the CADScor System's acoustic sensing platform identified heart failure with diagnostic accuracy comparable to a leading blood test, and with significantly fewer false positives OKLAHOMA CITY, Sept. 11, 2026...
- Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical TrialClearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the enrollment of the first patients with Alcohol Use Disorder (“AUD”) in its ongoing clinical trial evaluating CMND-100, the Company’s proprietary psychedelic-based treatment candidate for AUD.
- GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, will host a live company presentation on the development of the TriKE® platform for cancer treatment today, September 11, 2026, at 2:00 p.m. Eastern Time.
- Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration StatementAllarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor using its proprietary DRP® technology, announced that Allarity Acquisition Corp., a newly formed special purpose acquisition company (SPAC), has publicly filed a Registrat
- Elanco Animal HealthElanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results AnnouncementElanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail...
- HmediumFrost & Sullivan presents the "GLOBAL GENE THERAPY CRDMO TECHNOLOGY INNOVATION LEADERSHIP AWARD" to PackGene Biotech Inc.On August 4, the 20th Frost & Sullivan Global Growth, Innovation and Leadership (GIL) Summit and the 5th New Investment Event (the "2026 Frost & Sullivan New Investment Event") officially opened at Jing An Shangri-La, Shanghai.In conjunction with the Summit, the Celebratory Banquet for the 65ᵗʰ Anniversary of Frost & Sullivan Global and the 20ᵗʰ Anniversary of the GIL Summit in China was held, where the 2026 Frost & Sullivan Global Awards...
- Pharmaceutical Regulatory Affairs in Asia Online Training Set for March 3–5, 2027 — Registration Now OpenEvolving Asian pharma regulations are driving demand for expertise in market entry, clinical trials, product registration and lifecycle compliance for innovative drugs and generics.
- Patient-Derived Xenograft/PDX Model Market - Global Forecast 2026-2032Opportunities include integrated PDX platforms, humanized models, organoid pairing, AI analytics, annotated biobanks, precision oncology, and expansion across emerging research hubs.
- Form 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 10 09 2026] - (CGWL)FORM 8.3
- The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndromeThe U.S. FDA has granted Orphan Drug Designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of endogenous Cushing's syndrome Endogenous Cushing's Syndrome is a rare endocrine disorder driven in most cases by excess...
- Search JamClear Health Media Launches Four New iOS Clinical Assessment Apps and Updates Visual VerticalClear Health Media, an Australian developer of clinical software, today announced the release of four new iOS applications for clinical assessment, alongside a major update to its established Visual Vertical app."Many established clinical tests remain useful but are still administered using paper, stopwatches or specialised equipment," said Matthew Holmes of Clear Health Media. "Our aim is to use the capabilities already built into an...
- Persica Pharmaceuticals publishes new analysis of assay sensitivity in disc microbiology studies, reinforcing the potential for PP353 in vertebrogenic Lumbar Back PainLondon, UK, 11 September 2026 - Persica Pharmaceuticals Limited (“Persica”), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain (vLBP), today announced publication of a new analysis examining why previous disc microbiology studies have reported divergent findings on bacterial presence in spinal discs.